GlymaxX®: A Smart Way of Modulating Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

Natural Killer (NK) cell mediated tumor cell killing is one prominent mode of action for anti-cancer or anti-infectious antibodies. It relies on the antibody´s ability to recruit NK cells, which is enhanced when the antibody Fc glycan is devoid of fucose. Rather than knocking out any genes, ProBioGen redirects fucose synthesis by a heterologous enzyme that depletes the fucose pool inside the cell. Such cells produce afucosylated antibodies with up to 100x higher ADCC activity against tumor cells or virus-infected cells.

Our proprietary GlymaxX® technology can be applied to your standard host cell line. Alternatively, we can offer our own optimized GlymaxX host cell line, or even re-engineer existing producer clones.

We use GlymaxX for

  • novel antibody projects
  • biobetters (ADCC-enhanced originator mAb)
  • biosimilar projects (if adjusting a specific fucose level is crucial)

GlymaxX cell lines are stable and compatible with highest titer production processes. The unique advantage of the GlymaxX technology is that a single cell line is sufficient to produce both completely fucosylated or afucosylated antibodies and those with a defined intermediate fucosylation level. We adjust the level via fucose supplementation in the culture medium.

The technology is endorsed by licensees worldwide and applied to antibodies that are currently in clinical studies.

Advantages

  • Unique flexibility with one GlymaxX cell line for both afucosylated mAbs and fucolsyslated mAbs
  • Royalty-free, milestone-based business model
  • Clinically proven technology
  • Fast development (under 10 weeks)
Figure 1: Antibodies produced from GlymaxX-engineered cells contain a reduced amount of core-fucose and show an increased ability to recruit NK-cells and mediate an efficient antibody dependent cellular cytotoxicity (ADCC) response.
Figure 1: Antibodies produced from GlymaxX-engineered cells contain a reduced amount of core-fucose and show an increased ability to recruit NK-cells and mediate an efficient antibody dependent cellular cytotoxicity (ADCC) response.
Figure 2: Working principle of the GlymaxX Technology. In the absence of fucose, cells are unable to synthesize GDP-fucose via the salvage pathway. The de novo pathway, the dominant source of activated GDP-L-Fucose, is efficiently blocked by enzymatic co
Figure 2: Working principle of the GlymaxX Technology. In the absence of fucose, cells are unable to synthesize GDP-fucose via the salvage pathway. The de novo pathway, the dominant source of activated GDP-L-Fucose, is efficiently blocked by enzymatic co

Your Objectives

Are you looking to enhance your program or are you just curious about our company, services, and technologies? Connect with our team and we will get back to you shortly.

 

Note: You can revoke your consent at any time for the future by e-mail to info@probiogen.de
Detailed information on the handling of user data can be found in our Data Protection Statement.